The 2022 Inflation Reduction Act introduced modest drug pricing restrictions. In response, big pharma companies — which have seen record profits — are threatening to slow the rollout of a lifesaving drug.
  • Jaysyn@kbin.social
    18·
    1 year ago

    Between 2012 and 2021, drug companies spent substantially more on stock buybacks and dividends to reward shareholders than they did on research and development.

    Do you want your patents nationalized? Because that is how you get your patents nationalized.